Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.48 |
| ▸ | NOS1 | P29475 | 3/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | GGT1 | P19440 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517028 | 1.00 | NOS2 (0.48) | NOS2NOS1NOS3GGT1ARG1 | |
| SCHEMBL5518580 | 1.00 | NOS2 (0.48) | NOS2NOS1NOS3GGT1ARG1 | |
| Hydrochloric Acid SCHEMBL30568703 | 0.97 | NOS2 (0.52) | NOS2NOS1NOS3GGT1ARG1 | |
| Hydrochloric Acid SCHEMBL5520977 | 0.97 | NOS2 (0.52) | NOS2NOS1NOS3GGT1ARG1 | |
| Hydrochloric Acid SCHEMBL5520982 | 0.97 | NOS2 (0.52) | NOS2NOS1NOS3GGT1ARG1 | |
| SCHEMBL6835164 | 0.82 | KIF11 (0.41) | NOS2NOS1NOS3GGT1ARG1 | |
| SCHEMBL1667369 | 0.82 | KIF11 (0.41) | NOS2NOS1NOS3GGT1ARG1 | |
| SCHEMBL3703131 | 0.82 | KIF11 (0.41) | NOS2NOS1NOS3GGT1ARG1 | |
| SCHEMBL7281359 | 0.82 | — | — | |
| SCHEMBL7281364 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010689-A1 | Optically active 3,3'-dithiobis(2-amino-2methylpropionic acid) derivative and process for producing optically active 2-amino-3-mercapto-2-methylpropionic acid derivative | KANEKA CORPORATION (JP) | 2007-01-11 | — | — | US | claimed |
| EP-1666458-A1 | OPTICALLY ACTIVE 3,3 -DITHIOBIS(2-AMINO-2-METHYLPROPIONI C ACID) DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE 2-AMINO-3-MERCAPTO-2-METHYL-PROPIONIC ACID DERIVATIVE | KANEKA CORPORATION (JP) | 2006-06-07 | — | — | EP | claimed |
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8932828-B2 | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20130217629-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8288126-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120064573-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-03-15 | — | — | US | disclosed |
| US-20050026834-A1 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY, INC. | 2005-02-03 | — | — | US | disclosed |
| US-6753165-B1 | FOR RESIDUES THAT DO NOT FORM DISULFIDE BOND | BOLDER BIOTECHNOLOGY, INC. | 2004-06-22 | — | — | US | disclosed |
| US-20040018586-A1 | Lysis, denaturing, reducing Growth hormones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1284987-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1144613-A4 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2002-10-29 | — | — | EP | disclosed |
| WO-2001087925-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144613-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042175-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| US-4789475-A | BATHING ACTIVATED CHARCOAL IN POLYMER SOLUTION CONTAINING CHELATING AGENT, ACIDIFY | ENVIRONMENTAL CONCERNS, INC. (US) | 1988-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010689-A1 | Optically active 3,3'-dithiobis(2-amino-2methylpropionic acid) derivative and process for producing optically active 2-amino-3-mercapto-2-methylpropionic acid derivative | MPST, TPMT, ALAD | NOS2 1867/4885NOS1 2455/4885NOS3 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.